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ABSTRACT:
FBW7 (F-box and WD repeat domain-containing 7) or Fbxw7 is a tumor 
suppressor, which promotes the ubiquitination and subsequent degradation of 
numerous oncoproteins including Mcl-1, Cyclin E, Notch, c- Jun, and c-Myc. In turn, 
FBW7 is regulated by multiple upstream factors including p53, C/EBP-δ, EBP2, Pin1, 
Hes-5 and Numb4 as well as by microRNAs such as miR-223, miR-27a, miR-25, and 
miR-129-5p. Given that the Fbw7 tumor suppressor is frequently inactivated or 
deleted in various human cancers, targeting FBW7 regulators is a promising anti-
cancer therapeutic strategy. 
INTRODUCTION 
FBW7 (F-box and WD repeat domain-containing 7), 
also known as Fbxw7, has been found to be involved in 
numerous cellular processes including cell proliferation, 
apoptosis, cell cycle and differentiation [1-3]. It has 
been well documented that human FBW7 encodes three 
transcripts: isoform α, β and γ, generated by alternative 
splicings. All three isoforms contain conserved interaction 
domains in the C-terminus and various isoform-specific 
domains in the N-terminal region [4]. Interestingly, these 
α, β and γ isoforms display distinct cellular localization 
patterns, in the nucleoplasm, cytoplasm and nucleolus, 
respectively [5]. Importantly, FBW7 is considered as 
a tumor suppressor protein in large due to the fact that 
FBW7 targets multiple well-known oncoproteins including 
Cyclin E [2, 6-9], c-Myc [10-13], c-Jun [14-16], Mcl-1 
[17-19], and Notch-1[20, 21] for ubiquitination-mediated 
destruction. Consistent with the notion that FBW7 exerts 
its anti-tumor activity in various human malignancies, 
FBW7 mutation and/or deletion are frequently identified 
in a variety of human neoplasms [22]; for example, FBW7 
mutation rate in T-cell acute lymphoblastic leukemia is 
approximately 30% [22]. 
Although  recent  studies  have  identified  various 
downstream ubiquitin targets for FBW7, relatively little 
is known about the upstream signaling pathways that 
control FBW7 stability and cellular functions. To this end, 
there are some critical emerging evidence demonstrating 
that FBW7 tumor suppressor functions could be governed 
by multiple genes as well as upstream cellular signaling 
pathways. For example, it has been demonstrated 
that FBW7 is an unstable protein that undergoes self-
ubiquitination [23]. Furthermore, studies have shown 
that the Pin1 oncoprotein directly interacts with FBW7 
in a phosphorylation-dependent manner and promotes 
FBW7 self-ubiquitination and protein degradation [23]. 
Moreover, microRNAs (miRNAs) including miR-27, 
miR-25 and miR-223 have been reported to be involved 
in regulating the expression of FBW7 [24-27]. Therefore, 
in the following paragraphs, we will briefly summarize 
the newly identified substrates of FBW7 that have been 
reported in recent years that help further understanding 
the tumor suppressor role of FBW7. More importantly, 
we will mainly discuss how upstream genes and 
signaling pathways as well as miRNAs are involved in 
the regulation of the expression and stability of FBW7 to 
influence tumorigenesis.Oncotarget 2001 www.impactjournals.com/oncotarget
2.The new downstream substrates of FBW7 
Many studies from different groups have identified a 
growing list of specific substrates of FBW7 such as Aurora 
A [28], Cyclin E [8], c-Myc [29], c-Jun [14, 16], c-Myb 
[30-32], HIF-1α (Hypoxia inducible factor-1α) [33, 34], 
KLF5 (Kruppel-like factor 5) [35, 36], Mcl-1 (Myeloid 
cell leukemia-1) [18, 19], mTOR (mammalian target of 
rapamycin) [37, 38], NF1 (Neurofibromatosis type 1) [39], 
Notch [40, 41], NRF1 (Nuclear factor E2-related factor 
1) [42], JUNB [43, 44], and SREBP (Sterol regulatory 
element-binding proteins) [45, 46]. Recently, multiple new 
targets of FBW7 including MED13 (Mediator 13), KLF2 
(Krüppel-like factor 2), NF-κB2 [47, 48], and G-CSFR 
(Granulocyte  colony  stimulating  factor  receptor)  [49] 
have been also discovered. Since several excellent review 
articles have already summarized the roles of FBW7 in 
human cancers [20, 22, 50, 51], we will briefly discuss 
these newly identified FBW7 substrates that would help 
us to further understand the critical role of FBW7 in 
tumorigenesis. 
2.1 Mediator 13 (MED13)
The Mediator complex is a multi-subunit complex 
that is required for active transcription by RNA 
polymerase II [52, 53]. It is known that the Mediator 
complex consists of 26 different subunits in yeasts. The 
Mediator complex has been identified in mammals as well. 
Moreover, a specific module, also known as the kinase 
module or the CDK8 module, has been found in some of 
the MED complexes [54]. Interestingly, the smaller core 
Mediator without the kinase module has been reported to 
have a stimulatory effect on transcription, while the larger 
form including both the core and the kinase module exerts 
repressive effect on a subset of genes, suggesting that the 
kinase module could be a key regulatory factor to govern 
the transcription activity [54]. For example, the CDK8 
module reversibly associated with the Mediator core 
complex to control the Mediator-RNA Pol II interaction, 
leading to the regulation of transcription initiation and 
re-initiation. MED13 is the critical subunit for CDK8 
sub-module-dependent repression. Recent studies have 
demonstrated that Mediators exert their functions largely 
through interacting with and coordinating the action of 
many transcriptional co-activators or co-repressors [52]. 
For example, MED15 has been shown to be targeted 
by the Smad2/4 transcriptional activators to control 
the TGF-β signaling [55] and participate in the SREBP 
signaling [56] as well. Similarly, MED14 is required for 
Mediator-dependent activation of genes regulated by the 
glucocorticoid receptor [57], HNF4 (Hepatocyte nuclear 
factor  4)  [58],  and  PPARγ  (Peroxisome  proliferator-
activated receptor gamma) [59]. However, ubiquitination 
of transcription factors has been implicated in either 
activating or terminating their activities [60, 61], but it is 
unclear whether the ubiquitination pathway controls the 
activity of Mediators. 
To this end, a recent study has demonstrated that 
FBW7 could control the stability of MED13 [62]. Davis 
et al. revealed that FBW7 regulates CDK8 module-
Mediator interactions and targets MED13 and MED13L 
for proteasomal degradation. Specifically, FBW7 interacts 
with the CDK8-Mediator complex [62]. Moreover, FBW7 
was found to bind with several Mediator components 
including MED13. Notably, both MED13 and MED13L 
contain the optimal conserved phosphor-degron (CPD) 
consensus motif, through which FBW7 binds to its 
substrates [62]. To determine whether MED13/13L 
bound to FBW7, immunoprecipitation assays were 
conducted which showed that MED13/13L co-precipitated 
with FBW7 after proteasomal inhibition either by its 
inhibitor  bortezomib  or  by  using  dominant-negative-
Cullin1. Furthermore, the phospho-degron mutant 
form of Med13/13L (T326A mutation) failed to bind to 
FBW7 [62]. More importantly, MED13 and MED13L 
are phosphorylated at T326, which was shown to be 
required for FBW7-mediated degradation function [62]. 
Therefore, MED13 and MED13L are identified as bona 
fide FBW7 substrates. These important findings further 
suggested that FBW7 represents a novel mechanism for 
regulation of the Mediator activity to possibly influence 
the whole transcriptome [62]. However, additional in-
depth investigation is required to elucidate whether 
under physiological or pathological conditions, the tumor 
suppressor role of FBW7 is exerted in part via regulating 
the Mediator complex.
2.2 Kruppel-like factor 2(KLF2)
Krüppel-like factors (KLFs), members of the zinc 
finger family of transcription factors, have been found 
to be involved in the regulation of many biological 
processes, such as cell growth and differentiation [63, 
64]. Accumulated evidence has suggested that KLFs play 
a critical role in tumorigenesis [65-67]. For example, 
KLF2 has been shown to exert cell growth-inhibitory, pro-
apoptotic and anti-angiogenic functions. Consistent with 
this notion, KLF2 expression is diminished in a variety 
of human malignancies including prostate, breast, and 
ovarian cancers, suggesting that KLF2 may be a tumor 
suppressor gene [63]. Multiple studies have demonstrated 
that KLF2 could be regulated by upstream signaling 
pathways. For example, EZH2 (Enhancer of Zeste 
Homolog 2) was found to be one of the prominent genes to 
inhibit the expression of KLF2 [68]. Consistently, prostate 
or breast cancer patients with low expression of KLF2 and 
high levels of EZH2 have a shorter overall survival [68]. 
Additionally, Xie et al. reported that the Smurf1 (Smad 
ubiquitination regulatory factor 1) ubiquitin ligase targets 
KLF2 for ubiquitination and proteasomal degradation, Oncotarget 2002 www.impactjournals.com/oncotarget
leading to the regulation of its downstream genes such as 
CD62L and Wee1 in human cancer cells [69]. 
  Recently, Wang et al. revealed that KLF2 is a 
substrate of FBW7, suggesting that FBW7 may regulate 
its biological functions through the destruction of KLF2 
[70]. Specifically, two putative CPD sites on KLF2 were 
identified. In keeping with this finding, overexpression 
of FBW7 decreased KLF2 levels and shortened KLF2 
protein half-life [70]. Furthermore, FBW7 interacted 
with KLF2 in the nucleus and promoted ubiquitination 
of KLF2. More importantly, GSK3β (glycogen synthase 
kinase  3  beta)  was  identified  as  a  upstream  kinase 
to  specifically  phosphorylate  KLF2  on  the  T243  site 
within the identified phospho-degron [70]. Consistently, 
inhibition  of  GSK3β  increased  the  basal  levels  of 
KLF2 and extended KLF2 protein half-life [70]. Taken 
together, KLF2 is a physiological substrate of FBW7, and 
further research in this area could provide insights into 
identification of agents that aim to suppress KLF2 or for 
targeted therapeutic treatments in FBW7-deficient cells. 
2.3 Nuclear factor-κB2 (NF-κB2) 
The NF-κB pathway has been well characterized 
to play important roles in the processes of development 
and progression of human cancers [71-75]. The NF-
κB family is mainly composed of five proteins: RelA 
(p65), RelB, c-Rel, NF-κB1 (p50), and NF-κB2 (p52) 
[76]. NF-κB1 is sequestered in the cytoplasm through 
association with its inhibitors: IκBα and p100 proteins. It 
is known that p100 also serves as precursor of NF-κB2 
DNA-binding subunits [71]. The NF-κB is activated after 
it is dissociated from its inhibitors, and subsequently 
translocates to the nucleus for activation of NF-κB target 
genes [76, 77]. It is clear that IκBα and p100 could be 
phosphorylated by IKKβ and IKKα, respectively, resulting 
in the degradation of IκBα by the 26S proteasome and the 
processing of p100 into smaller forms (p52) [73]. NF-κB 
Figure 1: Illustration of upstream regulators that govern FBW7 expression in cancer. Several upstream genes including 
p53, EBP2, Hes-5, Numb4, Pin1, and C/EBP-δ are reported to regulate FBW7 expression. In addition, multiple microRNAs (miRNAs) 
such as miR-27a, miR-25, miR-129-5p, and miR-223 have also been demonstrated to regulate the expression of FBW7. C/EBP-δ: CCAAT/
enhancer-binding protein-δ; EBP2: Epstein-Barr nuclear antigen 1-binding protein 2; FBW7: F-box and WD repeat domain-containing 7; 
Hes-5: Hairy and Enhancer-of-split homologues 5; KLFs: Krüppel-like factors; Mcl-1: Myeloid cell leukemia-1; MED13: Mediator 13; 
mTOR: mammalian target of rapamycin; NF-kB2: Nuclear factor-κB2; Pin1: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1.Oncotarget 2003 www.impactjournals.com/oncotarget
has been found to be critically involved in tumorigenesis, 
exerting its oncogenic roles through the regulation of 
cell proliferation, differentiation, apoptosis, migration, 
invasion and angiogenesis [76, 78].
Three  independent  groups  recently  identified 
that NF-κB2/p100 is a substrate of FBW7 [47, 48, 79]. 
Notably, FBW7 interacts with p100 via a conserved 
phospho-degron. Moreover, FBW7 promoted degradation 
of p100, which was largely in a GSK3 phosphorylation-
dependent manner [79]. Overexpression of FBW7 
caused  enhanced  NF-κB  activity  in  FBW7  null  cells 
[47]. Consistently, FBW7 inactivation up-regulated p100 
levels, which subsequently suppressed the canonical NF-
κB1 signaling as p100 precursor could suppress NF-κB1 
transcriptional activities in an IκB−like manner. Busino 
et al. further identified that the FBW7α isoform controls 
p100 degradation [48]. More importantly, this group found 
that FBW7α silencing led to the induction of cellular 
apoptosis in multiple myeloma cells and xenotransplant 
models in part through regulating p100 degradation 
[48].  These  findings  provide  mechanistic  insights  for 
the regulation of NF-κB pathway by FBW7 through the 
destruction of NF-κB2/p100. 
2.4. Granulocyte colony stimulating factor 
receptor (G-CSFR)
G-CSFR, a critical regulator of granulopoiesis, has 
been reported to play a pivotal role in tumorigenesis [80-
82]. To this end, it has been shown that G-CSF/G-CSFR, 
though both autocrine and paracrine mechanism, enhanced 
cell survival and promoted cell growth in bladder cancer 
cells [83]. Yang et al. revealed that G-CSFR was critically 
involved in the development and progression of human 
colorectal cancers [84]. This group observed that G-CSFR 
was up-regulated in the human colorectal cancer setting. 
Notably, G-CSFR expression was correlated with tumor 
stage and tumor differentiation [84]. In support of their 
finding, Kunter et al. observed that truncated G-CSFR 
cooperated  with  the  PML-RARα  (promyelocytic 
leukemia-retinoic acid receptor alpha) oncogene to induce 
acute myeloid leukemia (AML) in mice [85]. 
Interestingly, there is emerging evidence 
demonstrating the possible role of the ubiquitin/protease 
system in regulating G-CSFR expression [86]. Moreover, 
studies have demonstrated that ubiquitination is required 
for  regulation  of  G-CSFR-mediated  cell  proliferation. 
G-CSFR mutations could disrupt its ubiquitination and 
subsequently cause aberrant receptor signaling, leading 
to leukemic transformation [87]. Recently, Lochab et al. 
found that FBW7 negatively controlled the granulocytic 
differentiation in part by targeting G-CSFR for degradation 
[49]. Furthermore, it has been shown that both FBW7 
and GSK3β are required for G-CSFR degradation. More 
importantly,  FBW7-mediated  destruction  of  G-CSFR 
suppressed STAT3 (signal transducer and activator of 
transcription 3) phosphorylation and activation [49]. 
In line with this finding, inhibition of FBW7 restored 
G-CSFR signaling and subsequently increased STAT3 
transcriptional activity. Interestingly, FBW7 also interacts 
with  and  degrades  a  truncated  mutant  of  G-CSFR, 
G-CSFR-T718, which was frequently found in AML [49]. 
Overall, these reports suggest that G-CSFR could be a 
substrate of FBW7 and aberrant upregulation of G-CSFR 
due to impairments in FBW7-mediated destruction could 
contribute to the development of AML.
3. Regulation of FBW7 
It is worth mentioning that most studies focus on 
discovering the ubiquitin targets of FBW7 ubiquitin ligase 
pathway. However, how FBW7 itself is regulated is largely 
unclear in human cancers. To this end, emerging evidence 
has demonstrated that several molecules such as p53, Pin1 
(Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1), 
C/EBP-δ  (CCAAT/enhancer-binding  protein-δ),  Hes-5 
(Hairy and Enhancer-of-split homologues 5), Numb, as 
well as microRNAs (miRNAs) including miR-27a and 
miR-223 have been found to regulate the expression of 
FBW7 [88-91]. In the following section, we will discuss 
the mechanisms how FBW7 is controlled by its upstream 
regulators. 
3.1 Regulation of FBW7 by p53
It has been well documented that p53 functions as a 
major tumor suppressor protein in the majority of human 
cancers [92-95]. The p53 tumor suppressor is found to 
be involved in cell growth, DNA synthesis and repair, 
differentiation, apoptosis, and cellular responses to a wide 
range of cellular stresses including heat shock, hypoxia, 
osmotic shock and DNA damage [96, 97]. Since p53 
mutation/deletion has been identified in, at least, 50% of 
all human cancers, cancers with a p53 mutation/deletion 
generally have bad prognosis due to poor response to 
therapeutics [98]. Previous studies have shown that p53 is 
negatively regulated by Mdm2, which is an E3 ubiquitin 
ligase that promotes the ubiquitination and destruction 
of p53 [99]. In support of this notion, Nutlin-3, a well-
characterized Mdm2 antagonist, can bind to Mdm2 in the 
p53-binding pocket and interfere with Mdm2-mediated 
p53 degradation, leading to the accumulation of p53 [100]. 
Further research has shown the effects of novel Mdm2 
inhibitors in maintaining p53 function [101, 102]. 
Recently,  FBW7  has  been  identified  as  a  direct 
bona-fide transcriptional target of p53 [88, 103]. Kimura 
et al. initially found that the expression of FBW7 was 
dramatically up-regulated by infection with adenovirus-
mediated transfer of wild-type p53 into the p53-deficient 
cells [88]. Moreover, they further demonstrated that the 
first exon of FBW7 contains a p53-binding site that has Oncotarget 2004 www.impactjournals.com/oncotarget
p53-dependent transcriptional activity. Furthermore, 
expression of FBW7β was induced in a p53-dependent 
manner after genotoxic stress such as UV irradiation, 
suggesting that FBW7 is a direct target of p53 [88]. 
Keeping abreast with this finding, Mao et al. subsequently 
reported that FBW7 mediates the critical role of p53 in 
response to DNA damage, indicating that FBW7 gene 
is a p53-dependent tumor suppressor gene involved in 
tumorigeneis [89]. Furthermore, this group found that 
inhibition of mTOR signaling pathway by rapamycin 
after exposure to radiation retarded tumor development 
in FBW7/p53 double heterozygous mice [104]. Taken 
together, these studies showed that targeting the p53 
signaling  pathway  could  potentially  influence  FBW7 
expression, which might provide a feasible approach to 
restore FBW7 expression for anti-cancer therapies. 
3.2 Regulation of FBW7 by C/EBP-δ 
C/EBP-δ  is  one  of  six  isoforms  of  the  C/EBP 
family that is a highly conserved family of leucine zipper 
type DNA-binding proteins [105, 106]. To exert its 
biological function, C/EBPs need to form homodimers or 
heterodimers with other C/EBP family members as well 
as other transcriptional factors including c-Fos and NF-κB 
(nuclear factor-κB) [105]. C/EBP-δ has been found to be 
involved in the regulation of growth and differentiation 
of a variety of cell types [107]. For example, forced 
expression  of  C/EBP-δ  inhibited  prostate  cancer  cell 
growth [108], suggesting a tumor suppressor function for 
C/EBP-δ. Moreover, it has been reported that C/EBP-δ 
initiates and maintains mammary epithelial cells at the 
G0 growth arrest. Furthermore, reduced C/EBP-δ gene 
expression due to promoter methylation has been found in 
breast cancer cell lines and primary breast tumors [109]. 
Recently,  Pawar  et  al.  reported  that  C/EBP-δ 
induced expression of the Cdc27 subunit of the APC/C 
(anaphase promoting complex/cyclosome), leading to the 
degradation of the Cyclin D1 and other APC substrates 
Cyclin B1, Skp2 and Plk-1 [110]. More recently, Roysarkar 
et al. identified a novel pathway by which Src suppressed 
C/EBP-δ in part through the SIAH2 (Seven in absentia 
homolog 2) E3 ubiquitin ligase [111]. Furthermore, it 
was recently reported that C/EBPδ can directly inhibit the 
expression of FBW7 [90]. This study demonstrated that 
C/EBPδ enhanced the mTOR/Akt/S6K1 signaling and 
augmented the translation and activity of HIF-1α through 
inhibiting FBW7 as both mTOR and HIF-1α are reported 
substrates of FBW7 [90]. Surprisingly, this study also 
revealed that C/EBPδ promoted breast tumor metastasis 
[90], indicating that further investigation is required to 
determine the molecular mechanisms, especially the 
contribution of FBW7 in mediating the cellular function 
of C/EBPδ in promoting tumor metastasis. 
3.3 Regulation of FBW7 by EBP2
Recently, Welcker et al. have identified that the 
EBNA1 (Epstein-Barr nuclear antigen 1)-binding protein 
2 (EBP2) directly binds to FBW7 and regulates FBW7’s 
nucleolar localization [112]. It is known that EBP2 is a 
small nucleolar protein that is essential for mammalian 
cell proliferation [113]. However, the exact role of EBP2 
in tumorigenesis is largely unknown. The study led by 
Dr. Clurman demonstrated that EBP2 serves as a pseudo-
substrate to target FBW7 to the nucleoli compartment 
[112]. Hence, it is important to further discuss the special 
role of EBP2 as a pseudo-substrate for FBW7. First, EBP2 
contains a canonical CPD motif at its extreme N terminus 
[112]. Second, EBP2 binding to FBW7 is regulated by 
phosphorylation of EBP2 by GSK3 [112]. Third, FBW7 
binding to EBP2 is uncoupled from the regulated turnover 
of endogenous EBP2, arguing that FBW7 binding to 
endogenous EBP2 appears insufficient for the degradation 
event of EBP2 in vivo [112]. Fourth, inactivation of 
FBW7 did not cause any noticeable changes to neither 
endogenous EBP2 abundance nor EBP2 stability [112]. 
Taken together, similar to SV40 T antigen [114], EBP2 
behaves mostly like the FBW7 pseudo-substrate that 
mainly serves to mediate its nucleolar localization. 
 3.4 Regulation of FBW7 by Pin1
It has been well documented that Pin1 is the only 
enzyme known that can isomerize specific Ser/Thr-Pro 
peptide bonds after phosphorylation to regulate their 
conformational changes with high efficiency [115-117]. 
These Pin1-induced conformational changes could regulate 
protein stability, catalytic activity, phosphorylation status, 
protein-protein interactions, and subcellular localization 
to further impact a wide range of cellular processes [118, 
119]. Because regulating these protein functions by Pin1 
is involved in diverse physiological and pathological 
processes, Pin1 deregulation is implicated in a number of 
diseases, including aging and age-related diseases, such 
as Alzheimer disease and cancer [120]. For example, Pin1 
is overexpressed in most human cancers. Notably, Pin1 
overexpression is associated with poor clinical outcomes 
in human cancer patients. Accumulated evidence has 
demonstrated that Pin1 exerts its oncogenic functions in 
large through activation of numerous oncogenes including 
Neu, Ras, c-Jun, Mcl-1, Notch-1, c-Myb, and inactivation 
of a large number of tumor suppressors such as p53, PML, 
and Foxos [121-123]. 
Recent studies have shown that Pin1 regulates 
the stability of several FBW7 substrates such as Mcl-
1 and c-Jun [124], indicating that Pin1 may be an 
upstream regulator of FBW7. Indeed, Min et al. found 
that Pin1 directly binds to FBW7 and disrupts FBW7 
dimerization [23]. Specifically, Pin1 interacts with FBW7 Oncotarget 2005 www.impactjournals.com/oncotarget
in a phosphorylation-dependent manner [23]. Moreover, 
Pin1 negatively regulated the stability of FBW7 through 
promoting FBW7 self-ubiquitination and degradation 
[23]. Mechanistically, Pin1 inhibited FBW7 dimerization, 
which is one of the key regulatory mechanisms for the 
regulation of FBW7. Furthermore, over-expression of Pin1 
showed reduced FBW7 protein abundance, leading to the 
inhibition of tumor cell proliferation and transformation 
[23]. Consistently, depletion of Pin1 caused higher 
expression of FBW7, subsequently decreased Mcl-
1 abundance, leading to enhanced Taxol sensitivity in 
cancer cells [23]. These results suggest that Pin1 reduces 
FBW7 expression, and thereby facilitating tumorigenesis. 
Taken together, this study provides the rationale for the 
development of specific Pin1 inhibitors as potential anti-
cancer agents. 
3.5 Regulation of FBW7 by Hes-5
Notch signaling pathway has been known to regulate 
various cellular processes including cell proliferation, 
apoptosis, migration, invasion, and angiogenesis in 
human malignancies [125-127]. Notch pathway is a 
ligand-receptor pathway with four characterized Notch 
receptors (Notch-1, 2, 3, 4) and five reported ligands 
(Dll-1, 3, 4 and Jagged-1, 2) [128, 129]. The Notch 
pathway is activated when Notch ligand binds to its 
receptor. Notch intracellular domain (NICD) is produced 
by the cleavage of membrane-bound Notch by multiple 
enzymes and released into the cytoplasm, subsequently 
translocates to the nucleus and activates its target genes 
including Hes-1, Hes-5, Hey-1, etc [128]. It has been well 
documented that Notch signaling pathway contributes 
to tumor development and progression [130-132]. 
Over-expression of Notch receptors and ligands, and 
their target genes has been found in a variety of human 
cancers [133-136]. For example, the expression of Hes-
1 and Hes-5 are up-regulated in advanced ovarian serous 
adenocarcinomas [137]. Notably, Hes-1 high expression 
could be a potential poor prognostic factor for ovarian 
cancer patients [137]. In line with this notion, Hes-1 and 
Hes-5 expressions were significantly higher in squamous 
cervical carcinomas [138]. Moreover, Hes-1 and Hes-5 
are positively associated with various prognostic factors 
in early-stage cervical carcinoma, suggesting that both 
Hes-1 and Hes-5 could be useful biomarkers to predict 
poor prognosis in patients with cervical carcinoma [138]. 
Study from Sancho and coworkers has demonstrated that 
Hes-5 directly represses transcription of FBW7β [139]. 
Furthermore, they revealed that the NICD/Hes-5/ FBW7β 
positive feedback loop underlies FBW7 haploinsufficiency 
[139]. However, further in-depth investigation is required 
to explore mechanistically how Hes-5 inhibits FBW7 
expression. 
3.6 Regulation of FBW7 by Numb4
Numb is originally found to be required for cell fate 
determination during the neuroblast division [140, 141]. 
Recently, Numb has been identified as a bona fide tumor 
suppressor gene in human cancers [142]. In breast tumors, 
frequent loss of Numb expression was observed and it 
was correlated with poor prognosis [143]. Similarly, the 
expression of Numb is frequently lost in NSCLC (non-
small cell lung carcinomas) [144]. Consistently, Numb 
deletions and low Numb expression have also been 
observed in pro-neural glioblastomas [145]. Numb has 
been reported to regulate multiple signaling pathways 
such as p53, Notch, and Hedgehog [142]. Study has 
suggested that Numb binds to and inhibits the E3 ubiquitin 
ligase Mdm2, which is responsible for p53 degradation, 
subsequently leading to up-regulation of p53 [146, 147]. 
Numb is able to bind the Itch, an E3 ubiquitin ligase, 
leading to the ubiquitination of Notch, suggesting that 
Numb could act as an adapter between Notch and Itch 
[148, 149]. It should be noted that Numb itself could be 
regulated by the E3 ligases including Siah-1 and LNX, 
resulting in its ubiquitin-dependent degradation [150, 151]. 
Recently, it has been shown that one of the predominant 
Numb isoform, Numb4, promoted FBW7 ubiquitin ligase 
assembly and activation, leading to enhanced Notch 
degradation [145]. However, further in-depth investigation 
is warranted to understand the physiological contribution 
of Numb4-mediated regulation of FBW7 expression in 
tumorigenesis in vivo. 
3.7 Regulation of FBW7 by the microRNAs 
(miRNAs) 
In recent years, miRNAs have been demonstrated 
to regulate gene expression through binding to the 3’UTR 
(3’ untranslated region) of target mRNAs, leading to 
either inhibition of translation of the encoded proteins or 
destabilization of the target mRNAs [152, 153]. It is well 
characterized that miRNAs could exert their oncogenic 
or tumor suppressor functions depending on the various 
target genes they control [154-156]. Accumulated evidence 
has also shown that multiple miRNAs including miR-27 
and miR-223 could regulate FBW7 expression [24, 91]. 
In the following paragraphs, we will discuss the potential 
function of miRNAs that are involved in the regulation of 
FBW7 to influence it anti-tumor roles. 
3.7.1 Regulation of FBW7 by miRNA-27 
It has been documented that miR-27a plays an 
oncogenic role in human cancers [157, 158]. For example, 
the oncogenic activity of miR-27a was observed in 
breast cancer cells due to the suppression of zinc finger Oncotarget 2006 www.impactjournals.com/oncotarget
ZBTB10, leading to increased expression of specificity 
proteins including Sp1, Sp3, and Sp4, and subsequently 
causing up-regulation and activation of Sp-dependent 
survival and angiogenic genes, such as Survivin, 
VEGF and VEGFR1 [159]. Consistently, another study 
demonstrated that miR-27a was highly expressed in 
breast cancer cells and inhibited the expression of tumor 
suppressor FOXO1 [160]. Zhu et al. found that miR-
27a was critically involved in drug resistance through 
regulating P-glycoprotein and MDR1 (multidrug resistant) 
expression in human cancer cells [161]. Similarly, down-
regulation of miR-27a reversed multidrug resistance 
of esophageal squamous cell carcinoma in part via 
regulation of P-glycoprotein, Bcl-2 and MDR1 [162]. 
In line with the oncogenic roles of miR-27a, Liu et al. 
reported that miR-27a is overexpressed in human gastric 
adenocarcinoma and promotes gastric cancer cell growth 
by inhibition of Prohibitin [163]. Furthermore, miR-27a 
exerts its oncogenic function via regulation of MET, 
EGFR, and Sprouty2 in lung cancer [164]. Ma et al. have 
further revealed that miR-27a enhanced cell growth, 
colony formation and migration by targeting Sprouty2 in 
pancreatic cancer cells [165]. Notably, miR-27a was found 
to regulate endothelial differentiation of breast cancer 
stem like cells [166]. Taken together, miR-27a could be 
possibly used as a target in the diagnosis and treatment of 
human cancers. 
Recently,  miR-27a  was  identified  to  inhibit  the 
expression of FBW7. Wang et al. reported that FBW7 
is a potential miR-27a target. Consistently, there is an 
inverse correlation between miR-27a expression and 
FBW7 levels in human tumor samples [167]. Lerner et 
al. further discovered that miR-27a suppresses FBW7 
during specific cell cycle phases [26]. Specifically, miR-
27a suppresses FBW7 expression, leading to a reduction 
in ubiquitin-mediated degradation and turnover of FBW7 
substrate, cyclin E. Overexpression of FBW7 caused 
dysregulation of cyclin E, resulting in altered cell cycle 
progression [26]. Moreover, miR-27a was found to be 
overexpressed and inversely associated with FBW7 
expression in leukemia [26]. In further support of this 
concept, overexpression of miR-27a has been observed 
in colon cancer cell lines and colon cancer stem cells 
[168]. Notably, miR-27a knockdown increased FBW7 
levels and subsequently decreased the expression of 
FBW7 substrates such as c-Myc, c-Jun and Notch-1 in 
colon cancer [26]. Furthermore, miR-27a overexpression 
promotes cell growth, whereas miR-27a knockdown 
inhibits cell proliferation in vitro and tumor formation in 
vivo possibly through regulating FBW7 [26]. Collectively, 
these findings suggest that miR-27a exerts its oncogenic 
functions in part through negative regulation of the FBW7 
tumor suppressor. 
3.7.2 Regulation of FBW7 by miR-223
Recent evidence has suggested that miR-223 may 
play a key role in human cancers [169-171]. Numerous 
studies have found overexpression of miR-223 in various 
types of human cancers including hepatocellular carcinoma 
[172], T-ALL [173], ovarian cancer [174], gastric cancer 
[25], esophageal squamous cell carcinoma [175], and 
bladder cancer [176]. Moreover, overexpression of miR-
223 has been found in patients with lymph node metastasis 
and metastatic disease at an advanced pathological stage in 
gastric carcinoma [25]. High expression of miR-223 was 
also found to be associated with poor survival in gastric 
carcinomas [177], ovarian cancer [174], and esophageal 
squamous cell carcinoma [175]. Furthermore, miR-
223 promotes gastric cancer invasion and metastasis by 
targeting tumor suppressor EPB41L3 [177]. Interestingly, 
miR-223 was found to have a tumor suppressor function 
by inhibiting migration and invasion through targeting 
Artemin, a tumor metastasis-related gene, in human 
esophageal carcinoma [178]. In line with this notion, it has 
been shown that miR-223 is overexpressed in the multiple 
step progression of Barrett’s esophagus and modulates 
drug resistance via targeting PARR1 [179]. Interestingly, 
in a separate report, down-regulation of miR-223 was 
identified in hepatocellular carcinoma, while re-expression 
of miR-223 caused an inhibitory effect on cell viability 
in hepatocellular carcinoma cell lines [180]. Therefore, 
further study is warranted to determine the physiological 
function of miR-223a in various human tumor settings.
A growing body of evidence has recently 
demonstrated that miR-223 regulates FBW7 expression. 
Xu et al. found that the over-expression of miR-223 
suppressed FBW7 expression, resulting in increased 
Cyclin E protein levels and activities, and subsequently 
causing genomic instability [24]. Conversely, reduced 
miR-223 expression resulted in increased FBW7 
expression and decreased Cyclin E activity, indicating 
that FBW7 can be modulated directly by miR-223 
[24]. Li et al. also reported that FBW7 protein levels 
were inversely correlated with miR-223 expression in 
gastric tumor tissues [25]. Re-introduction of miR-223 
suppressed FBW7 expression at the post-transcriptional 
level in gastric cancer cell lines [25]. Consistent with this 
finding, Kurashige and colleague reported similar inverse 
relationship between miR-223 and FBW7 in esophageal 
squamous cell carcinoma [175]. This group also identified 
FBW7 as a functional downstream target of miR-223 
in esophageal cancers [175]. Recently, Mavrakis et al. 
found that Mcl-1 levels are increased in mouse leukemias 
expressing miR-223 through down-regulation of FBW7 
[181]. However, further in-depth research is needed in 
order to fully understand how miRNA-223 regulates 
FBW7 in human carcinogenesis. Oncotarget 2007 www.impactjournals.com/oncotarget
3.7.3 Regulation of FBW7 by miR-25
Several lines of evidence has defined that miR-25 is 
dysregulated in human cancers [182-184]. For example, 
miR-25 was observed to be down-regulated in human 
colon cancer tissue. Moreover, studies have shown that 
miR-25 could inhibit cell growth and migration through 
repression of Smad7 in colon cancer cells [185]. Another 
study showed that miR-25 could inhibit cell proliferation 
and colony formation through targeting oncogene EZH2 
(enhancer  of  zeste  2)  in  thyroid  carcinoma  [186].  In 
contrast, miR-25 has been found to be up-regulated in 
esophageal squamous cell carcinoma (ESCC) tissues and 
associated with lymph node metastasis and TNM (Tumor, 
Node and Metastasis) stage. This study also revealed 
that miR-25 promoted ESCC migration and invasion via 
inhibiting E-cadherin expression [187]. Consistently, miR-
25 promotes cell aggressiveness through down-regulation 
of desmpcollin-2 and subsequently redistributing adheren 
junctions and activating β-Catenin signaling in ESCC 
[188]. In addition, miR-25 has also been found to be 
highly expressed in ovarian cancer and regulates apoptosis 
through targeting pro-apoptotic Bim [189]. Additionally, 
miR-25 promotes apoptosis resistance through targeting 
TNF-related apoptosis inducing ligand (TRAIL) death 
receptor-4 in cholangiocarcinoma [190]. Recently, miR-
25 has been shown to inhibit FBW7 expression and 
caused up-regulation of c-myc and KLF5 to promote 
reprogramming  of  mouse  fibroblast  cells  to  iPSCs 
(induced pluripotent stem cells) [191]. However, further 
studies are warranted to explore whether miR-25 regulates 
FBW7 in cancer stem cells in the future. 
3.7.4 Regulation of FBW7 by miR-129-5p
Mounting evidence suggested that miR-129-5p may 
also be involved in tumor development and progression 
[192, 193]. For example, it has been demonstrated that 
miR-129-5p is required for histone deacetylase inhibitor-
induced cell death in thyroid cancer cells [194]. Liu et 
al. found that miR-129-5p suppressed tumor growth and 
reduced cell migration through inhibition of VCP (Valosin 
containing protein) in hepatocellular carcinoma [195]. Zhi 
et al. reported that miR-129-5p was up-regulated in serum 
in AML patients, indicating that miR-129-5p could be a 
potential biomarker for detecting AML [196]. Recently, 
miR-129-5p was identified to regulate FBW7 expression. 
Over-expression of miR-129-5p up-regulated FBW7 
expression, however; the underlying mechanism is unclear 
[197]. Accordingly, further study is necessary to define 
how miR-129-5p controls FBW7 expression and whether 
this process is involved in tumorigenesis. 
3.8 Regulation of FBW7 by other factors
Emerging evidence has suggested that FBW7 could 
be regulated by several other factors such as NF-κB1 
[198], FAM83D (family with sequence similarity 83, 
member D) [199]. For example, Huang et al. found that 
NF-κB1 inhibited FBW7 expression and subsequently 
suppressed its target c-Myc protein degradation [198]. 
Wang et al. reported that FAM83D promoted cell 
proliferation and migration as well as invasion through 
downregulation of FBW7 and upregulation of FBW7 
target mTOR [199]. Another study showed that SREBP2 
regulated miR-182 targeting FBW7, leading to a feedback 
pathway to regulate SREBP transcriptional activity 
[200, 201]. Moreover, various stress stimuli have been 
found to induce FBW7 expression [202]. Interestingly, 
various stress stimuli regulated different FBW7 isoforms. 
Specifically, FBW7β is induced by all the stress stimuli 
such as aphidicolin, fetal calf serum, vinblastine mostly in 
a p53-dependent manner, whereas expression of FBW7α 
and γ was responded to limited stress stimuli [202]. 
CONCLUSIONS 
In conclusion, FBW7 functions as a tumor 
suppressor, which is frequently mutated or depleted 
in various types of human cancers. FBW7 exerts its 
anti-tumor activity by targeting a ever-growing list of 
ubiquitin substrates including MED13, KLF2, and Mcl-
1. More importantly, the E3 ligase activity of FBW7 is 
regulated by many upstream genes such as p53, C/EBP-δ, 
EBP2, Pin1, Hes-5 and Numb4. Moreover, miRNAs 
including miR-223, miR-27a, miR-25, and miR-129-59p 
can also regulate the expression of FBW7. Since FBW7 
is governed by upstream factors, restoring FBW7 tumor 
suppressor function through regulation of these factors 
could be useful to design novel therapeutic means to 
treat cancer patients. Indeed, it has been demonstrated 
that a natural dietary agent genistein inhibited miR-223 
expression and subsequently up-regulated FBW7, leading 
to cell growth inhibition and apoptosis in pancreatic cancer 
cells [203]. Therefore, targeting FBW7 upstream genes 
and its regulatory miRNAs could open a novel therapeutic 
window for developing more potent treatments of human 
cancers. 
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